Menu
Search
|

Menu

Close
X

Agios Pharmaceuticals Inc AGIO.OQ (NASDAQ Stock Exchange Global Select Market)

99.55 USD
-- (--)
As of Jun 20
chart
Previous Close 99.55
Open --
Volume --
3m Avg Volume 154,786
Today’s High --
Today’s Low --
52 Week High 99.77
52 Week Low 50.91
Shares Outstanding (mil) 57.61
Market Capitalization (mil) 5,576.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
43
FY16
70
FY15
59
EPS (USD)
FY18
-1.631
FY17
-6.743
FY16
-5.058
FY15
-3.140
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.88
Price to Sales (TTM)
vs sector
135.15
8.30
Price to Book (MRQ)
vs sector
6.62
4.32
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.35
LT Debt to Equity (MRQ)
vs sector
0.00
12.89
Return on Investment (TTM)
vs sector
-47.12
13.21
Return on Equity (TTM)
vs sector
-57.86
15.18

EXECUTIVE LEADERSHIP

David Schenkein
President, Chief Executive Officer, Director, Since 2013
Salary: $568,000.00
Bonus: --
Andrew Hirsch
Chief Financial Officer, Since 2016
Salary: $126,667.00
Bonus: --
Scott Biller
Chief Scientific Officer, Since 2010
Salary: $416,890.00
Bonus: --
Christopher Bowden
Chief Medical Officer, Since 2014
Salary: $436,091.00
Bonus: --
Steven Hoerter
Chief Commercial Officer, Since 2016
Salary: $363,125.00
Bonus: $375,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

88 Sidney St
CAMBRIDGE   MA   02139-4137

Phone: +1617.6498600

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

SPONSORED STORIES